The global antiviral drugs market to grow at a CAGR of 9.48% during the period 2017-2021.
The report, Global Antiviral Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
The latest trend gaining momentum in the market is technological advancements. The new hybridoma technique is a novel approach toward the development of monoclonal antibodies, which are selective in nature. This technique will not only have a positive impact against viral diseases but also decrease the cost of the overall treatment. It can be expected that antiviral agents, which were above $100 and could be used to control an epidemic effectively, can now be produced at 1% of its original cost.
According to the report, one of the major drivers for this market is stockpiling by public healthcare agencies. The CDC estimates that government organizations such as the WHO are also taking initiatives to secure public health during future outbreak of viral diseases by increasing the antiviral drugs stock. The CDC manages the Strategic National Stockpile, which includes storage of bulk quantities of antiviral medications for public health emergencies.
- Bristol-Myers Squibb
- F. Hoffmann-La Roche
- Gilead Sciences
Other prominent vendors
- Johnson & Johnson
.Key Topics Covered:
PART 01: Executive summary
PART 02: Research Methodology
PART 03: Introduction
PART 04: Disease Overview
PART 05: Market landscape
PART 06: Pipeline analysis
PART 07: Market segmentation by therapies
PART 08: Market segmentation by MOA
PART 09: Geographical segmentation
PART 10: Decision framework
PART 11: Drivers and challenges
PART 12: Market trends
PART 13: Competitive Landscape
PART 14: Key vendor analysis
PART 15: Appendix
For more information about this report visit http://www.researchandmarkets.com/research/gmfn39/global_antiviral